Background: A platinum-containing anti-cancer agent, oxaliplatin (L-OHP), is known to induce peripheral neuropathy, including erectile dysfunction (ED) as a side effect, while Gosha-jinki-gan (GJG) is a traditional Japanese herbal medicine mainly used for peripheral neuropathy.

Aim: To investigate the effect of GJG on L-OHP-induced ED in rats.

Methods: Twelve-week-old male Wistar/ST rats were categorized into the following groups: Sham, Sham+GJG, L-OHP, and L-OHP+GJG (each n = 10). The L-OHP and L-OHP+GJG groups were injected intravenously with L-OHP (4 mg/kg) for 2 consecutive days in the first week. Statistical significance was determined using Bonferroni’s multiple comparison test.

Outcomes: At the end of the study period, erectile function was evaluated by measuring intracavernosal pressure (ICP) and mean arterial pressure (MAP) after cavernous nerve stimulation. Western blot analysis was used to assess the neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) levels, and quantitative polymerase chain reaction was used to assess the expression of phosphodiesterase-5 (PDE-5) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1.

Results: The ICP/MAP ratio of L-OHP rats (0.34 ± 0.06) was significantly lower than that of Sham rats (0.67 ± 0.03, P < .01), however, the ICP/MAP ratio of L-OHP+GJG rats (0.55 ± 0.01) was significantly higher than that of L-OHP rats (P < .01). There were no significant differences in the nNOS and eNOS protein expression between both groups (P > .05). GJG administration significantly decreased PDE-5 and NADPH oxidase-1 messenger RNA expressions in the L-OHP+GJG group.

Clinical Translation: This animal model study suggests that GJG might be effective for erectile function in cancer survivors.

Strengths & limitations: Our study identified that GJG had no notable side effects in the treated group. Further investigation of the cavernous nerve would also help elucidate the mechanism of GJG effect, which is a limitation of this study.

Conclusion: We found that GJG administration improved L-OHP-induced ED by improving transcriptional PDE-5 expression. Kataoka T, Kawaki Y, Kito Y, et al. Gosha-Jinki-Gan Improved Erectile Dysfunction Caused by Anti-Cancer Agent Oxaliplatin by Decreasing Transcriptional Expression of Phosphodiesterase-5 in Rats. Sex Med 2022;10:100484.

Received October 14, 2021. Accepted December 19, 2021.

1Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan;
2Department of Hospital Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan

Copyright © 2021 The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Key Words: Gosha-Jinki-Gan; Anticancer Agents; Erectile Dysfunction; Phosphodiesterase-5
INTRODUCTION

There are many cancer patients worldwide, and several chemotherapy agents are administered in their treatment. Oxaliplatin (L-OHP), a third-generation platinum-containing anticancer drug, is widely used for colorectal cancer, and colorectal cancer is the third most common type of cancer among adults in the Western world.1,2 We previously reported that L-OHP caused erectile dysfunction (ED) in rats,3 while neuropathy is a common adverse effect of the platinum agent.4 The development of neuropathy is a major concern that may negatively influence a patient’s quality of life. Mols et al. reported that 42% of men who had been treated with L-OHP complained of erectile problems.5 ED also influences a patient’s quality of life, and appropriate treatment is required.

Gosha-jinkī-gan (GJG) is a Japanese herbal medicine (Kampo) that contains a mixture of extracts from 10 raw botanical materials in fixed proportions.6 In Japan, GJG has been widely used for the treatment of diabetic neuropathy without severe adverse events.7 GJG was also effective in treating chemotherapy-induced peripheral neuropathy.8 GJG was reported to prevent neuropathy without weakening the efficacy of anti-cancer agents.9 Therefore, GJG may be safely used for the treatment of ED associated with anti-cancer drug treatment. However, the effectiveness of GJG for ED has not been clarified. Our hypothesis is “Is GJG effective for the ED caused by the anti-cancer agent oxaliplatin?”. In this study, we investigated the effect of GJG on erectile function after the administration of the anti-cancer agent oxaliplatin using a rat model.

METHODS

Animals

Twelve-week-old male Wistar and/or ST rats were purchased from Japan SLC, Inc. (Hamamatsu, Japan). All experimental protocols were approved by the ethics review board of Nagoya City University and conducted in accordance with our institutional standards for the care and use of animals (H25-P-09).

Treatment Protocols

In total, 40 rats were assigned to 4 groups (each n = 10): L-OHP, L-OHP with GJG (L-OHP+GJG), Sham, and Sham with GJG (Sham+GJG). L-OHP (Yakult Honsha Co., Ltd. Tokyo, Japan) was dissolved in a 5% glucose solution just before administration of the 5% glucose solution containing 1% GJG. After 4 weeks, the rats were evaluated for erectile function.

Measurement of Biological Parameters

At the end of the treatment period, blood samples were obtained from the rats via the vena cava. After coagulation and centrifugal separation at 800 g for 20 minutes at 4°C, serum samples were stored at -80°C until analysis. The biological parameters were analyzed by Fujifilm Vet Systems Co., Ltd. (Chofu, Tokyo, Japan).

Examination of Erectile Function

Intracavernos pressure (ICP) was measured by electrical stimulation as previously reported.3,10-14 Rats from each group were briefly anesthetized using isoflurane (Mylan, Canonsburg, PA, USA) using inhalation anesthesia apparatus (Nakazawa Seisakusho, Funabashi, Japan). The carotid artery was cannulated for continuous monitoring of the mean arterial pressure (MAP), and the left crus of the corpus cavernosum was cannulated using a 23-G needle for continuous ICP monitoring. The pressure transducer was connected through an amplifier to a data acquisition board (PowerLab 2/26; ADInstruments Pty. Ltd., Bella Vista, Australia). Stainless steel bipolar wire electrodes (Unique Medical, Osaka, Japan) and a pulse generator (Nihon Kohden, Tokyo, Japan) were used for penile stimulation with the following parameters: 1 minute at 5 V, 1–16 Hz, and a square wave duration of 5 minutes. Erectile function was evaluated using the maximum ICP/MAP ratio, as ICP is influenced by systemic arterial pressure.

Western Blot Analysis

Western blot analysis was performed as previously reported.3,15-16 We extracted protein from the corpus cavernosum using Cell Culture Lysis Reagent (Promega Corp., Madison, WI, USA) in accordance with the manufacturer’s instructions. Total protein concentration was quantified using BCA Protein Assay Reagent (Pierce Biotechnology, Rockford, IL, USA). Samples containing 30 mg of total protein were separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were transferred onto polyvinylidene difluoride membranes (ImmobilonTM; Millipore Corp., Bedford, MA, USA). The membranes were then blocked for 1 hour using 5% skim milk in Tris-buffered saline (pH 7.5)–Tween 20 (TBST) at room temperature, and they were sequentially incubated with mouse monoclonal anti-neuronal nitric oxide synthase (nNOS) (1:100;
Abcam, Tokyo, Japan), anti-endothelial nitric oxide synthase (eNOS) (1:100; Abcam), and mouse monoclonal anti-β-actin (1:5,000; Sigma, Saint Louis, MO, USA) in 5% skim milk at 4°C overnight. After washing with TBST, anti-mouse immunoglobulin G (IgG) conjugated with horseradish peroxidase (1:5,000; GE Healthcare, Little Chalfont, UK) was added for 1 hour at room temperature, and the membranes were washed again with TBST. Protein bands were visualized using enhanced chemiluminescent (Amersham Biosciences, Little Chalfont, UK) and ImageQuant LAS 4000 mini (GE Healthcare). Semiquantitative densitometry was performed using ImageJ software (NIH, Bethesda, MD, USA).

Real-Time Quantitative Polymerase Chain Reaction

Real-time quantitative polymerase chain reaction (qRT-PCR) analysis was performed as previously reported.10,13,17 Total RNA was extracted from corpus cavernosum samples using TriPure Isolation Reagent (Sigma-Aldrich, St. Louis, MO, USA) according to the manufacturer’s instructions. Using a ReverTra Ace-α kit (Toyobo, Osaka, Japan), 1 μg of total RNA was reverse-transcribed into complementary DNA, which served as the template for qRT-PCR performed using the KAPA SYBR Fast qPCR Kit (Roche, Pleasanton, CA, USA). The primer sequences are shown in Table 1. Amplification and detection were performed using the CFX96 Real-time System (Bio-Rad, Hercules, CA, USA). The thermal cycler conditions were as follows: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C, 15 s at 95°C, 15 s at 60°C, and 15 s at 95°C to analyze the dissociation curve. Primer specificity was verified via analysis of the dissociation curve. Target gene expression was quantified relative to β-actin expression by using the comparative C_T method. All measurements were performed in triplicate.

Statistical Analyses

Results were expressed as box-and-whisker plots and the mean ± standard error of the mean (SEM). Statistical significance was determined by a Bonferroni’s multiple comparison test using in

Table 1. Real-time quantitative polymerase chain reaction primer sequences

| mRNA                  | Forward Sequence | Reverse Sequence |
|-----------------------|------------------|------------------|
| NADPH oxidase-1       | 5’-GCTGGGCTTACTTACT-3’ | 5’-TCCTGGCGGATAAAA-3’ |
| PDE-5                 | 5’-CACAGTGCTATTTG-3’  | 5’-CAATCAAGCAATGCAA-3’  |
| β-actin               | 5’-TGTTGGSTGGTGCTATC-3’  | 5’-CATCGTACTCTG-3’  |

mRNA = messenger RNA; NADPH = nicotinamide adenine dinucleotide phosphate; PDE-5 = phosphodiesterase-5.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** (A) Changes in the bodyweight of the Sham, Sham with Goshaz-jinki-gan (Sham+GJG), Oxaliplatin (L-OHP), and L-OHP with GJG (L-OHP+GJG) rats. (B) Changes in the food intake of the Sham, Sham with Goshaz-jinki-gan (Sham+GJG), Oxaliplatin (L-OHP), and L-OHP with GJG (L-OHP+GJG) rats. Data are reported as means ± standard error of the mean (n = 10 per group). N.S. indicates not significant using Bonferroni’s multiple comparison test for analysis.
Table 2. Biological parameters of Sham, Sham with Gosha-jinki-gan (Sham+GJG), Oxaliplatin (L-OHP), and L-OHP with GJG (L-OHP+GJG) rats

| Biological parameter | Unit       | Sham      | Sham+GJG  | L-OHP     | L-OHP+GJG | P-value |
|----------------------|------------|-----------|-----------|-----------|-----------|---------|
| Na                   | µEq/L      | 142.5 ± 1.7| 142.0 ± 1.1| 143.0 ± 1.9| 142.5 ± 2.3| > 0.05  |
| Cl                   | µEq/L      | 95.3 ± 0.6 | 95.3 ± 1.0 | 96.8 ± 1.1 | 92.5 ± 1.7 | > 0.05  |
| K                    | µEq/L      | 7.2 ± 0.7  | 7.1 ± 0.3  | 6.1 ± 0.4  | 6.3 ± 0.3  | > 0.05  |
| Ca                   | mg/dL      | 11.9 ± 0.4 | 12.2 ± 0.2 | 11.9 ± 0.3 | 11.6 ± 0.3 | > 0.05  |
| P                    | mg/dL      | 10.5 ± 0.6 | 10.0 ± 0.2 | 9.7 ± 0.9  | 11.0 ± 1.9 | > 0.05  |
| Total protein        | g/dL       | 6.0 ± 0.2  | 6.1 ± 0.2  | 6.1 ± 0.2  | 6.0 ± 0.1  | > 0.05  |
| Albumin              | g/dL       | 3.4 ± 0.1  | 3.4 ± 0.1  | 3.4 ± 0.1  | 3.4 ± 0.1  | > 0.05  |
| GOT (AST)            | IU/L       | 114.3 ± 18.7| 104.8 ± 5.6| 111.0 ± 18.9| 116.5 ± 18.9| > 0.05  |
| GPT (ALT)            | IU/L       | 84.5 ± 14.9| 76.5 ± 4.5 | 74.5 ± 12.5| 71.8 ± 8.8 | > 0.05  |
| LDH                  | IU/L       | 460.0 ± 99.3| 293.5 ± 33.8| 568.0 ± 181.0| 775.5 ± 439.7| > 0.05  |
| ALP                  | IU/L       | 1359 ± 65.6| 1205 ± 106 | 1258 ± 109 | 1216 ± 116 | > 0.05  |
| Amylase              | IU/L       | 3382 ± 128 | 3220 ± 111 | 3588 ± 133 | 3263 ± 78  | > 0.05  |
| Lipase               | IU/L       | 9.8 ± 0.3  | 9.5 ± 0.5  | 9.8 ± 0.5  | 9.8 ± 0.3  | > 0.05  |
| BUN                  | mg/dL      | 19.0 ± 1.2 | 18.8 ± 1.0 | 19.8 ± 0.3 | 17.8 ± 1.0 | > 0.05  |
| Creatinine           | mg/dL      | 0.33 ± 0.02| 0.33 ± 0.03| 0.35 ± 0.03| 0.30 ± 0.00| > 0.05  |
| Total cholesterol    | mg/dL      | 69.0 ± 5.7 | 68.8 ± 1.8 | 77.3 ± 3.9 | 75.3 ± 3.6 | > 0.05  |
| Triglyceride         | mg/dL      | 99.3 ± 13.3| 82.0 ± 7.9 | 61.8 ± 5.6 | 83.0 ± 7.8 | > 0.05  |

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; GOT = glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transaminase; LDH = lactate dehydrogenase.

Data are reported as the mean ± standard error of the mean (n = 4 per group). P-values were analyzed by Bonferroni’s multiple comparison test.

Figure 2. Measures of erectile function in Sham, Sham with Gosha-jinki-gan (Sham+GJG), Oxaliplatin (L-OHP) and L-OHP with GJG (L-OHP+GJG) rats.

(A) Representative tracings of intracavernous pressure (ICP) and arterial pressure changes during electrical field stimulation (EFS, 16 Hz) of the cavernous nerve. (B) Erectile function according to the ICP and/or mean arterial pressure (MAP) ratio. Data are presented as box-and-whisker plots (n = 6 per group). *P < .05, **P < .01 vs each group using Bonferroni’s multiple comparison test for analysis.
RESULTS

Biological Parameters

Figure 1A shows body weight changes during the study. There was no statistically significant difference in mean body weights at 4 weeks (Sham, 405.5 ± 2.5 g; Sham+GJG, 397.5 ± 5.9 g; L-OHP, 381.5 ± 2.8 g; L-OHP+GJG, 368.3 ± 10.0 g; \( P > .05 \)). Figure 1B shows food intake during the study. There was no significant difference in food intake in any of the observation periods. Table 2 shows the biological parameters of the rats. There were no significant differences in electrolyte levels, liver function, renal function, and lipid levels (\( P > .05 \)).

Erectile Function

Figure 2A shows representative tracings of the ICP and atrial pressure changes during electrical stimulation of the cavernous nerve. ICPs in the L-OHP group appeared to be lower than those in the Sham group. Figure 2B shows the ICP/MAP ratios for different stimulation frequencies. The L-OHP group (0.34 ± 0.06) exhibited significantly lower ratios than the Sham group (0.67 ± 0.03; \( P < .01 \)) at 16Hz. The L-OHP+GJG group (0.55 ± 0.01) exhibited significantly higher ratios than the L-OHP group (\( P < .01 \)). There was no significant difference between the Sham and Sham + GJG groups (0.70 ± 0.05; \( P > .05 \)).

nNOS and eNOS Protein Analysis

Figure 3 shows the nNOS and eNOS protein expression levels. There were no significant differences in nNOS and eNOS protein expression between the groups (\( P > .05 \)).

Biomarker Messenger RNA Expression Analysis

Figure 4 shows the messenger RNA (mRNA) expression levels for biomarkers related to erectile function. Expression analysis of the oxidative stress marker nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-1 revealed that the expression of NADPH oxidase-1 was significantly higher in the L-OHP group than in the Sham group (\( P < .01 \)). This expression significantly decreased in the L-OHP+GJG group compared to the L-OHP group (\( P < .05 \)). The expression of phosphodiesterase (PDE)-5 was significantly higher in the L-OHP group than in the Sham group (\( P < .01 \)), whereas the expression was significantly lower in the L-OHP + GJG group than in the L-OHP group (\( P < .01 \)).
In this study, the Japanese traditional medicine GJG improved the ED caused by the administration of an anti-cancer agent, L-OHP, in rats (Figure 2). Electrolyte abnormalities were not seen in the L-OHP + GJG administration group (Table 2). Hepatic dysfunction and renal dysfunction were also not observed in the L-OHP + GJG administration group. These data showed that no notable side effects were observed in the treated group.

Peripheral neuropathy is a known side effect of L-OHP.2 We investigated nNOS protein expression in the corpus cavernosum (Figure 3A). The expression of nNOS protein in the L-OHP group had not changed. However, L-OHP has been reported to reduce the number of nNOS-immunoreactive neurons.19 Song et al. reported that cavernous nerve injury decreased eNOS protein levels in a mouse model.20 In this study, the expression of eNOS did not change in the L-OHP group; moreover, GJG administration did not affect NOS expression (Figure 3B). In our previous study, L-OHP significantly decreased the eNOS protein levels,3 but in this study, the eNOS expression remained unchanged in the L-OHP group. After 2-3 days of receiving oxaliplatin, the food intake also decreased. So, administering the Gosha-Jinki-Gan in a stable dose was difficult. After this experiment, we conducted additional experiments by changing the frequency and duration of oxaliplatin administration. These additional analyses showed that ED develops even with 4 mg/kg L-OHP administered on day 1 and 2 for 4 weeks. Whereas, the food intake during the experimental course was stable, so we conducted another experiment with this dose, in which the conditions were milder than those in previous studies that demonstrated no change in the eNOS protein expression. However, GJG had no effect on the Nitrous oxide production. Hence, more investigation would be necessary for other target.

To investigate other mechanisms underlying the effects of GJG, we examined inflammation in the corpus cavernosum (Figure 4). Nakanishi et al. reported that GJG suppressed inflammation in the spinal cord of the mouse.21 Our analyses revealed that L-OHP increased the expression of the pro-oxidant NADPH-oxidase 1. However, GJG decreased NADPH-oxidase 1 in the corpus cavernosum of rats. It was possible that the dose of 1% GJG was effective for the inflammatory response caused by L-OHP in the corpus cavernosum. Further investigation using the cavernous nerve would also help elucidate the mechanism of GJG, which is a limitation of this study.

L-OHP can induce oxidative stress and cause dysfunction of the spinal nitric oxide and/or cyclic guanosine monophosphate (cGMP) pathway.22, 23 In the smooth muscles of the corpus cavernosum, the increased cGMP relaxes the smooth muscle and causes an erection.24, 25 In contrast, PDE-5 works to metabolize cGMP, so when PDE-5 increases, erectile function...
Inhibitor administration was effective for refractory ED.\textsuperscript{11, 33} Therefore, GJG improved the erectile function of rats by inhibiting cGMP metabolization and increasing the relaxation of smooth muscle. In the arterial smooth muscle cells, high oxygen concentrations can increase the PDE-5 expression.\textsuperscript{28, 29} Muzaffar S et al. reported that a superoxide from NADPH oxidase upregulates type-V PDE in the human vascular smooth muscle cells.\textsuperscript{30} In this study, we speculated that the expression of PDE-5 increased because of the increasing superoxide levels by the upregulation of NADPH-oxidase 1 by L-OHP; however, GJG suppressed the PDE-5 expression by suppressing the activity of NADPH-oxidase-1. In this study, the protein levels of PDE-5 were not found; hence, future studies are warranted that measured the protein level and activity of PDE-5. PDE-5 inhibitors have been widely used for treating ED.\textsuperscript{31, 32} Our previous study reported that chronic PDE-5 inhibitor administration was effective for refractory ED.\textsuperscript{11, 33} Because GJG decreased PDE-5 expression, GJG might be effective for other types of ED. Moreover, PDE-5 inhibitors costs about approximately US$10-20 the United States dollars per dose, while GJG costs about approximately US$0.5 dollars per dose. Therefore, GJG is a economical cost-effective treatment choice and could be useful for chronic administration in cancer survivors.

GJG is composed of 10 herbal medicines; however, the specific component of GJG that was effective for improving the erectile function of rats has not been clarified, which we consider as a limitation. The second limitation of this study was that the dose of GJG was not changed and that we did not observe a washout period because GJG was fed to the rats in a mixed diet. The 1% GJG we used for our experiments can be converted to indicate GJG 1 g/kg/day.\textsuperscript{34} In the future studies, researchers should consider changing the dose and including a washout period.

CONCLUSION

We found that administering GJG improved the L-OHP-induced ED in rats by improving the transcriptional expression of PDE-5. This animal model study indicated that GJG might be effectively improve the erectile function for male cancer survivors.

ACKNOWLEDGMENTS

This work was supported in part by Grants-in-Aid for Scientific Research (KAKENHI, 18K16703 and 20K09563) from the Japan Society for the Promotion of Science (JSPS) and RFOM 15-04 from the Research Foundation for Oriental Medicine (RFOM). In this study, GJG bulk was provided by Tsumura & Co. We acknowledge the assistance of the Research Equipment Sharing Center at the Nagoya City University.

Corresponding Author: Tomoya Kataoka, PhD, Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; E-mail: kataoka@med.nagoya-cu.ac.jp

Corresponding Author: Kazunori Kimura, PhD, Department of Clinical Pharmaceutics, Graduate School of Medical Sciences, Nagoya City University, 1-Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan; E-mail: kkimura@med.nagoya-cu.ac.jp

STATEMENT OF AUTHORSHIP

Conceptualization, T.K. and K.K.; Data curation, T.K., Y.K., Y. K., J.S., T.M., Y.H., and Y.M.; Formal analysis, T.K. Y.K., Y. K., and J.S.; Funding acquisition, T.K., Y.H., and K.K.; Investigation, T.K., Y.K., Y. K., T.M., J.S., Y.H., and Y.M.; Methodology, T.K. and Y.H.; Project administration, T.K.; Supervision, Y.H., A.S., Y.K., Y.M., Y.FH. and K.K.; Writing-original draft, T.K. and K.K.; Writing-review & editing T.K. and K.K.

REFERENCES

1. André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Luocovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343–2351.
2. Batra A, Rigo R, Sheka D, et al. Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World J Gastrointest Oncol 2020;12:604–618.
3. Kataoka T, Mori T, Suzuki J, et al. Oxaliplatin, an anticancer agent, causes erectile dysfunction in rats due to endothelial dysfunction. J Sex Med 2021;18:1337–1345.
4. Baviera AF, Olson K, de Paula JM, et al. Acupuncture in adults with chemotherapy-induced peripheral neuropathy: a systematic review. Rev Lat Am Enfermagem 2019;27:e3126.
5. Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2351–2357.
6. Kuriyama A, Endo K. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer 2018;26:1051–1059.
7. Tawata M, Kurihara A, Nitta K, et al. The effects of goshajinkigan, a herbal medicine, on subjective symptoms and vibratory threshold in patients with diabetic neuropathy. Diabetes Res Clin Pract 1994;26:121–128.
8. Cascella M, Muzio MR. Potential application of the Kampo medicine goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy. J Integr Med 2017;15:77–87.
9. Ushio S, Egashira N, Sada H, et al. Goshajinkigan reduces oxaliplatin-induced peripheral neuropathy without affecting antitumour efficacy in rodents. Eur J Cancer 2012;48:1407–1413.
10. Kataoka T, Hotta Y, Maeda Y, et al. Testosterone deficiency causes endothelial dysfunction via elevation of asymmetric dimethylarginine and oxidative stress in castrated rats. J Sex Med 2017;14:1540–1548.

11. Kataoka T, Hotta Y, Ohno M, et al. Limited effect of testosterone treatment for erectile dysfunction caused by high-estrogen levels in rats. Int J Impot Res 2013;25:201–205.

12. Kataoka T, Hotta Y, Maeda Y, et al. Assessment of androgen replacement therapy for erectile function in rats with type 2 diabetes mellitus by examining nitric oxide-related and inflammatory factors. J Sex Med 2014;11:920–929.

13. Kataoka T, Sanagawa A, Suzuki J, et al. Influence of anticancer agents on sexual function: an in vivo study based on the US FDA Adverse Event Reporting System. Andrology 2021 (in press).

14. Kataoka T, Hotta Y, Yamamoto Y, et al. Effect of late androgen replacement therapy on erectile function through structural changes in castrated rats. Sex Med 2021;9:100348.

15. Hotta Y, Ohno R, Kataoka T, et al. Effects of chronic vardenafil treatment persist after end of treatment in rats with acute arteriogenic erectile dysfunction. J Sex Med 2012;9:1782–1788.

16. Yamamoto S, Hotta Y, Maeda K, et al. High salt loading induces urinary storage dysfunction via upregulation of epithelial sodium channel alpha in the bladder epithelium in Dahl salt-sensitive rats. J Pharmacol Sci 2017;135:121–125.

17. Kishimoto T, Kataoka T, Yamamoto Y, et al. High salt intake impairs erectile function in salt-sensitive rats through mineralocorticoid receptor pathway beyond its effect on blood pressure. J Sex Med 2020;17:1280–1287.

18. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452–458.

19. McQuade RM, Carbone SE, Stojanovska V, et al. Role of oxidative stress in oxaliplatin-induced enteric neuropathy and colonic dysmotility in mice. Br J Pharmacol 2016;173:3502–3521.

20. Song KM, Jin HR, Park JM, et al. Intracavernous delivery of stromal vascular fraction restores erectile function through production of angiogenic factors in a mouse model of cavernous nerve injury. J Sex Med 2014;11:1962–1973.

21. Nakanishi M, Nakae A, Kishida Y, et al. Go-sha-jinki-Gan (GJG) ameliorates allograft in chronic constriction injury-model mice via suppression of TNF-α expression in the spinal cord. Mol Pain 2016;12:1744806916656382.

22. Mihara Y, Egashira N, Sada H, et al. Involvement of spinal NR2B-containing NMDA receptors in oxaliplatin-induced mechanical allodynia in rats. Mol Pain 2011;7:8.

23. Areti A, Komirishetty P, Kalvala AK, et al. Rosmarinic acid mitigates mitochondrial dysfunction and spinal glial activation in oxaliplatin-induced peripheral neuropathy. Mol Neurobiol 2018;55:7463–7475.

24. Hotta Y, Kataoka T, Kimura K. Testosterone deficiency and endothelial dysfunction: nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sex Med Rev 2019;7:661–668.

25. Abdel Aziz MT, Mostafa T, Atta H, et al. Putative role of carbon monoxide signaling pathway in penile erectile function. J Sex Med 2009;6:49–60.

26. Lin CS. Phosphodiesterase type 5 regulation in the penile corpora cavernosa. J Sex Med 2009;6:203–209.

27. Gonzalez-Cadavid NF, Rajfer J. The two phases of the clinical validation of preclinical translational mechanistic research on PDE5 inhibitors since Viagra’s advent. A personal perspective. Int J Impot Res 2019;31:57–60.

28. Farrow KN, Groh BS, Schumacker PT, et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ Res 2008;102:226–233.

29. Farrow KN, Lee KJ, Perez M, et al. Brief hyperoxia increases mitochondrial oxidation and increases phosphodiesterase-5 activity in fetal pulmonary artery smooth muscle cells. Antioxid Redox Signal 2012;17:460–470.

30. Muzaffar S, Shukla N, Bond M, et al. Superoxide from NADPH oxidase upregulates type 5 phosphodiesterase in human vascular smooth muscle cells: Inhibition with iloprost and NON-Oate. Br J Pharmacol 2008;155:847–856.

31. Fode M, Jensen CFS, Østergren PB. Sildenafil in postprostatectomy erectile dysfunction (perspective). Int J Impot Res 2019;31:61–64.

32. Ahmed WS, Geethakumari AM, Biswas KH. Phosphodiesterase 5 (PDE5): structure-function regulation and therapeutic applications of inhibitors. Biomed Pharmacother 2021;134:111128.

33. Hotta Y, Hattori M, Kataoka T, et al. Chronic vardenafil treatment improves erectile function via structural maintenance of penile corpora cavernosa in rats with acute arteriogenic erectile dysfunction. J Sex Med 2011;8:705–711.

34. Imamura T, Ishizuka O, Aizawa N, et al. Goshajinki gan reduces transmitter proteins and sensory receptors associated with C fiber activation induced by acetic acid in rat urinary bladder. Neurourol Urodyn 2008;27:832–837.